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Web-based personalised information and
support for patients with a neuroendocrine
tumour: randomised controlled trial
L. D. de Hosson1†, G. Bouma1†, J. Stelwagen1, H. van Essen1, G. H. de Bock2, D. J. A. de Groot1, E. G. E. de Vries1 and
A. M. E. Walenkamp1*
Abstract
Background: Patients with a neuroendocrine tumour (NET) frequently have physical and psychosocial complaints.
Aim of this study is to determine whether a web-based, personalised information and support system (WINS)
reduces distress and/or improves patients’ perception of and satisfaction with information received.
Methods: Patients with NET, stratified for those newly diagnosed (< 6 months, n = 28) and with a longer history of
disease (n = 74), were randomised between standard care (n = 49) and intervention, consisting of access to WINS
(n = 53). Primary outcome was change of distress and satisfaction with perceived information measured with the
distress thermometer and problem list and the QoL questionnaire (QLQ)-INFO25. The intervention group also
completed a questionnaire based on the technical acceptance model (TAM).
Results: We observed no difference in distress slope and slope of median global score on perceived information
and satisfaction between the intervention and control group. Interestingly, 55% of patients wished to receive more
information at baseline.
Conclusions: In a population of NET patients, access to WINS did not improve indicators for distress, perception of
information and satisfaction with information received, more than standard care only. Despite the need for more
information, the WINS does not have added value to the information and care provided by health care
professionals.
Clinical trial registration: ClinicalTrials.gov (NCT02472678). Registered 6th Jan 2015. Retrospectively registered
1st May 2017.
Keywords: Neuroendocrine tumour, Information, Quality of life, Internet, Web-based system
Background and aims
Neuroendocrine tumours (NETs) are rare tumours with
an incidence of 3.5/100,000 per year in the last decade
[1, 2]. Patients with NET may experience various symp-
toms from the tumour mass, the output of hormones
secreted by the tumour, treatment and accompanying
side effects [3]. Patients are frequently metastasized at
the time of diagnosis. Patients with metastasized NETs
have a relatively long median survival: 100 months for
NETs of the small intestine and 60months for pancre-
atic NETs [4]. Patients with NET have a lower quality of
life (QoL) compared with the general population [5]. For
patients with NET it is difficult to find meaningful and
understandable information about their diagnosis.
Anxiety, higher depression, and stress negatively influ-
enced QoL in patients with NET. Self-efficacy, more
social support and optimism are associated with better
QoL [6]. Previous research in cancer patients and cancer
survivors has consistently shown that high satisfaction
with the information received and satisfied information
needs were related to better quality of life and lower
emotional distress for anxiety and depression [7, 8].
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Furthermore internet-based support programs are effect-
ive in improving psychosocial and physical symptoms in
cancer patients [9]. In addition, in an observational study
of NET patients using qualitative interviews, 7 out of 18
patients found the internet to be a useful source of
general information [10].
We previously developed a web-based personalised in-
formation and support system (WINS), for patients with
NETs with the aim of reducing distress and/or improv-
ing patients’ perception of and satisfaction with informa-
tion received.
A pilot study demonstrated the feasibility of using
WINS in patients with NET [11]. Based on these results
and on patients’ recommendations, we developed the
current version of WINS, which was used in the present
study. The aim of this randomised trial is to determine
whether WINS reduces distress and/or improves NETs




Between May 2015 and October 2016, we included 105
patients in the study (Fig. 1). The trial was ended when
91 patients completed the study. Of the 91 patients who
completed the study, 46 (12 newly diagnosed) patients
were randomised to the intervention group. Baseline
characteristics of included patients are shown in Table 1.
At baseline, 78 patients had previously visited the inter-
net for information on NET before randomisation. At
baseline, 50 patients stated that they wanted to receive
more information compared to 31 at end of study. At
baseline, 4 patients answered that they would prefer to
receive less information. At the end of study no patients
gave this answer.
Primary outcomes
The median distress level in both groups was 3 before
and after study (Tables 2, 3). A significant difference
in distress was found for only the domain ‘social
problems’; at end of study 12 patients in the control
group of 45, reported social problems compared to 7
patients at baseline. Four patients at end of study in
the intervention group of 46 patients, compared to 10
patients at baseline were found to have social prob-
lems (p < 0.01). The median global score for patients’
perception of and satisfaction with information
received, did not improve in the intervention group
relative to the control group (Tables 2, 4). Interest-
ingly, 53 and 57% of patients in the control and inter-
vention group wish to receive more information,
respectively. After the intervention less patients in the
control group (31%) wished to receive more informa-
tion versus the patients in the intervention group
(38%).
Most patients agreed with the statements mentioned
in the additional questionnaire (Table 5). During the
study, the median number of visits to the website was 3
(range 2–4), and only 3 patients used the opportunity to
ask questions and consult with the researcher for clinical
purposes. Other questions were about technical or
logistical aspects.
Newly diagnosed patients
The planned subgroup analysis for newly diagnosed
patients did not detect any difference in this subgroup
regarding the global score for distress and the problem
Fig. 1 Consort diagram
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Newly diagnosed patients n (%) 25 (27) 13 (29) 12 (26)
Sex (female) n (%) 42 (46) 23 (51) 19 (41)
Age mean in years (sd) 62 (8) 63 (7) 62 (10)
Location of primary tumor: n (%)
Pancreas 21 (23) 9 (20) 12 (26)
Intestine 53 (58) 26 (58) 27 (59)
Stomach/duodenum 3 (3) 2 (4) 1 (2)
Colorectal 2 (3) 2 (4) 1 (2)
Bronchopulmonal 1 (1) 1 (2) 0 (0)
Appendix 1 (1) 1 (2) 0 (0)
Unknown/other 9 (10) 4 (9) 5 (11)
Duration of disease in months: mean (SD) 41 (56) 33 (38) 50 (66)
Disease grade: n (%)
1 57 (63) 27 (60) 30 (65)
2 21 (23) 12 (27) 9 (20)
Unknown 13 (14) 6 (13) 7 (15)
Marital state (Married) n (%) 75 (82) 34 (76) 41 (89)
Education (Polytechnic or university) n (%) 33 (37) 16 (36) 17 (38)
Internet use n (%)
Daily 86 (96) 40 (91) 46 (100)
For information about the disease 78 (87) 37 (82) 41 (89)
Treatment during study: n (%)
Surgery 7 (8) 2 (4) 5 (11)
PRRT 2 (2) 1 (2) 1 (2)
SSA 64 (70) 32 (71) 32 (70)
Systemic treatment other than SSA 17 (19) 9 (20) 8 (17)
Treatment before study: n (%)
Surgery 52 (57) 26 (58) 26 (57)
PRRT 2 (2) 0 (0) 2 (4)
Radiotherapy 3 (3) 0 (0) 3 (6)
SSA 65 (71) 32 (71) 33 (72)
Systemic treatment other than SSA 23 (25) 12 (26) 11 (24)
Other (RFA) 1 (1) 0 (0) 1 (2)
n = number, PRRT = peptide receptor radionucleide therapy, RFA = radiofrequency ablation, SSA = somatostatin analogue
Table 2 Primary outcome, distress and global score of perceived information and satisfaction (EORTC QLQ-INFO25)










Distress level (0–10) 3 (1–5) 3 (1–5) 3 (2–5) 3 (1–5) NS
Global Score EORTC QLQ-INFO25 (0–100) 49 (37–55) 51 (42–59) 45 (33–56) 38 (47–57) NS
Higher scores mean more distress and more/better information and satisfaction
NS = no significant difference, Pre Median =median score at baseline, Post median =median score a 12 weeks, range = interquartile range
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domains (Additional file 1 and Additional file 2:
Tables S1 and S2).
In this subgroup, perceived information and satisfac-
tion did not differ between the control group and inter-
vention group. We found a difference for only one item,
‘information about the disease in the QLQ-INFO25’;
after 12 weeks this score decreased in the intervention
group and increased in the control group (p = 0.046).
Most patients agreed with the statements on the
self-constructed questionnaire (Additional file 1 and
Additional file 2: Table S5).
Discussion
In this randomised trial we found that WINS did not
reduce distress nor improved NETs patients’ perception
of and satisfaction with information received. We found
the same results in the pre-planned subgroup analyses
with newly diagnosed patients.
Developing a web-based system (WBS) providing pa-
tient detailed information corresponding to their individ-
ual needs and wishes is difficult [12]. The contact and
communication with health care professionals remains a
crucial source of information and support for patients
with NET. Other web-based studies have shown that
web-based technology does not replace patient-provider
communication [13]. In one such study, in which 103
cancer patients received questionnaires about the WBS,
the highest rated component was receiving an answer
from a nurse. In another trial in 766 patients receiving
chemotherapy for solid cancers, patients were rando-
mised to either standard care or to standard care plus a
web-based self-reporting system. Physicians received
Table 3 Distress (Distress thermometer and Problem List)










Practical problems 0 (0–4) 0 (0–4) 0 (0–4) 0 (0–5) NS
Social problems 0 (0–0) 0 (0–4) 0 (0–0) 0 (0–0) 0.002
Emotional problems 3.5 (0–13) 6 (0–12) 7 (1–16) 7 (1–16) NS
Spiritual problems 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) NS
Physical problems 8 (4–18) 10 (6–19) 13 (7–21) 12 (5–20) NS
Global score 14 (7–32) 17 (6–44) 21 (12–41) 21 (7–44) NS
Higher scores mean more distress (from problems). The p-value shows the differences between the pre-post changes of the control group versus the
intervention group
NS = no significant difference, Pre Median: median score at baseline, Post median; median score a 12 weeks, range; interquartile range
Table 4 Perceived information and satisfaction (EORTC QLQ-INFO25)











Disease 50 (33–58) 50 (42–65) 50 (33–60) 50 (33–67) NS
Medical tests 67 (44–67) 67 (44–67) 67 (56–67) 67 (28–56) NS
Treatments 44 (25–56) 39 (33–56) 44 (28–56) 8 (0–27) NS
Other services 17 (0–25) 17 (8–33) 17 (6–23) 8 (0–27) NS
Different location of care facilities 0 (0–33) 33 (0–33) 0 (0–33) 0 (0–33) NS
How to help yourself 33 (0–33) 33 (0–33) 17 (0–33) 33 (0–33) NS
Satisfaction with information 67 (33–67) 67 (33–67) 67 (33–67) 67 (33–67) NS
Helpfulness of information 67 (50–67) 67 (67–67) 67 (67–67) 67 (33–67) NS
Percentage of patients
Received written information 91 91 78 80
Received cd/video 2 2 2 0
Wish to receive more info 53 31 57 38
Wish to receive less info 2 0 2 0
Higher scores indicate more/better information and satisfaction. The p-value shows the differences between the pre-post changes of the control group versus the
intervention group
cd = compact disk, NS = no significant difference, Pre Median =median score at baseline, Post median =median score a 12 weeks, range = interquartile range
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symptom printouts at visits and nurses received e-mail
alerts when participants of the intervention group re-
ported severe or worsening symptoms. In this trial, QoL
improved (34% vs. 18%; p < 0.001) and OS was higher
(31 vs. 26 months; p = 0.03) in the intervention group
compared to the group receiving standard care only
[14]. Another example, that web-based technology does
not replace patient-provider communication, was pre-
sented in a randomised controlled study of a website
providing additional information and symptom
self-management support in 325 breast and prostate
cancer patients. Distress was used as the primary
endpoint [15]. Compared to the control group, which
was given uniform resource locators (URLs) of publically
available cancer information websites, an improvement
for patients in the intervention group was found only on
the subscale ‘global distress index’.
A potential explanation for these findings could be
that NET patients obtain sufficient information by usual
care that all patients received. In our trial all patients
had easy access to specialists and nurses during standard
care, which might have satisfied their need for informa-
tion. Furthermore, patients were able to get information
from the NET patient association [16]. We did not use a
control group receiving no information which can be
regarded as a limitation of our study.
At baseline half of the patients in both groups
indicated that they wanted more information about the
disease. During study period, the need for more informa-
tion decreased in both groups. A decline in the need for
information during the course of the disease was
observed in other studies analysing patients with other
types of cancer [17, 18]. Furthermore, patients only vis-
ited the WBS sporadically. Patients were not requested
to visit the website more frequent, which also could be
seen as a limitation. Sporadically visiting a WBS was also
reported in other trials using a WBS [15, 19]. In a quali-
tative interview study, one of the three main reasons
reported for not using a WBS was that patients had
sufficient access to information elsewhere [20]. In two
other studies, in patients with cancer and brain tumours,
patients reported that they avoided using the WBS
because they did not want to be reminded of their suf-
fering or, because they had a preference for other kinds
of communication [20, 21].
Another limitation is that we could only analyze
patients with outcome data on the second assessment,
as the primary endpoint was the pre-post change of
distress and satisfaction with perceived information. For
that, the 14 (13%) of the patients who withdrew early, or
who did not complete the end-of-study questionnaires
were excluded from the analysis.
Conclusion
In NET patients, WINS did not improve distress scores
and patients’ perception of or satisfaction with informa-
tion received, compared to patients receiving standard
care only. Despite the need for more information, the
WINS does not have added value to the information and
care provided by health care professionals.
Methods
Participants
Eligible participants were adult patients treated at the
University Medical Centre Groningen Department of
Medical Oncology for NET grade 1 or 2 (World Health
Organization 2010 classification) with the primary
tumour at any site of origin, and who were proficient in
Dutch (both reading and writing). Patients with a life
expectancy of less than 3months as evaluated by their
doctor were excluded. The study was approved by the
medical ethical committee of the UMCG and registered
in ClinicalTrials.gov (NCT02472678). All patients gave
written informed consent.
Randomisation process and study procedure
For a detailed description of study procedures, see
Additional file 1 and Fig. 1. The included patients were
stratified randomised for those diagnosed within 6
months and those with disease duration ≥6months.
Patients were randomised 1:1 to the control group, re-
ceiving standard care, or the intervention group, which
received standard care with additional access to WINS.
At baseline patients’ socio-demographic and disease
characteristics, internet use and health care use were
collected. Patients in both groups received a question-
naire about their perception of and satisfaction with the
received information and their QoL. The control group
was also given a questionnaire about distress and
problems. After returning the questionnaires, patients in
the intervention group received log-in information for
website access. At the first website visit, the patients
Table 5 Questionnaire based on patients’ opinion and use of





The website is useful to me 4 (4–4)
The information at the website is interesting to me 4 (4–4)
I find this a site that adds value 4 (3–5)
I have a positive attitude towards the website 4 (4–5)
I would recommend the site to peers 4 (3–5)
How often do you visit the website 3 (2–4)
Higher scores indicate more agreement with the statement (except for
number of visits)
Median: median score (at 12 weeks), range; interquartile range
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were asked to complete a questionnaire about distress
and problems at baseline, before they were given access
to the other items on the website. At 12 weeks
follow-up, all patients were asked to complete the ques-
tionnaires again, with an additional questionnaire to
asses empowerment. Patients in the intervention group
were asked to complete the questionnaire about distress
and problems at the WINS instead of completing it with
pen and paper. Furthermore, they were requested to
complete an additional questionnaire about their use of
and opinion about WINS.
Standard care and study intervention
All patients received standard care. At their first visit at
the Department of Medical Oncology patients are
informed verbally about the disease and they meet the
oncology nurse to become acquainted. During follow-up
visits, the medical oncologist evaluates the general
well-being, discusses possible treatment options and
treatment side-effects (if applicable) and answers ques-
tions of the patient. Between follow-up visits all patients
could consult an oncology nurse 24 h a day, 7 days a
week by telephone. Furthermore, patients were able to
get information from the NET patient association [16].
If physical and/or psychosocial problems require more
in-depth discussion, investigation or treatment, patients
can receive a consultation with the oncology nurse,
oncologist or other health care professionals.
In the intervention group, the questionnaire about
distress and problems served as a self-screening tool for
physical and psychosocial problems. By using WINS,
patients could obtain personalised information about
reported problems. Self-screening was performed by the
online version of the Dutch Distress Thermometer (DT)
and Problem List (PL). Immediately after completion of
the DT and PL. Patients received online information on
the physical and psychosocial problems they reported on
the digital PL. This information comprises: a) descrip-
tion and background information of their reported
problem b) advice on how to cope with the problem
(self-help) c) what health care professional could be con-
sulted when self-help insufficiently alleviates problems.
On the WINS, patients could also find general informa-
tion about the disease, read about the experiences of
other NET patients and find links to other relevant
websites. Any time, patients could send an e-mail with a
question or request a telephone consultation with the
investigators (physicians experienced in treating NET
patients) in case of questions, problems or request
further referral’.
Outcome measurements
Illness-related patient characteristics were extracted from
the medical records at baseline. All other measurements
were performed by self-report questionnaires. Selection of
endpoints was based on the results of the pilot study [11].
According to our pre planned protocol our primary end-
point was the combined endpoint of distress the change
in distress level combined with change in global score of
perception of and satisfaction with information received.
Distress was measured using the validated Dutch Distress
Thermometer (DT) and Problem list (PL) [22]. This ques-
tionnaire consisted of one single item that asks patients to
indicate the amount of overall distress experienced during
the past week and a PL with several items divided into five
domains. Higher scores indicate more distress or more
problems. The EORTC QLQ-INFO25 in Dutch was used
to evaluate patients’ perception of and satisfaction with
information received [23]. Higher scores indicate better
perceived information provision. The measures of the vali-
dated QLQ-INFO25 are categorized and scored according
to the EORTC guidelines. For a more detailed descripition
of the questionnaires, see our pilot study. An additional
questionnaire, only given to the intervention group at end
of study was based on the constructs of ‘perceived useful-
ness’ and ‘attitude and usage’ from the revised Technology
Acceptance Model and on a self-constructed question on
a 5-point likert scale; if patients recommend WINS to
other NET patients [24].
Sample size calculation
Sample size calculation was based on the results of the
pilot study, in which only newly diagnosed patients were
included. To detect a significant difference in the change
of the distress thermometer between the control and
intervention group, using an independent t-test with an
effect size of 0.6, we calculated that 90 patients had to
be included (Additional file 1). Taking into account a
dropout of 15%, we included 105 patients in this study,
Statistical analysis
For descriptive statistics, mean and standard deviation
(sd) for normal distribution and median and interquar-
tile range for other distributions and frequencies were
calculated for all measures. The scores of the EORTC
questionnaires were calculated according to the EORTC
guidelines [23, 25, 26]. An independent t-test or Mann
Whitney U test was performed, depending on the kind
of distribution, to detect differences between the
pre-post changes of standard care complemented with
the WINS versus standard care alone. Given the negative
findings of the outcome we did not correct for multiple
comparison issues. Subgroup analysis was performed in
newly diagnosed patients. Differences were considered
significant at p < 0.05. Analyses were performed with the
software package SPSS, version 23 for Windows (SPSS,
Inc., Chicago, IL, USA). Patients who were lost to follow
up were excluded from analysis.
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Additional file1: Supportive Information. (DOCX 24 kb)
Additional file 2: Table S1. Distress in newly diagnosed patients
(Distress thermometer and Problem List). Table S2. Perceived
information and satisfaction with information in newly diagnosed
patients (EORTC QLQ-INFO25). Table S3A. Quality of life in newly
diagnosed patients (EORTC QLQ-C30). Table S3B. Quality of life in newly
diagnosed patients (EORTC QLQ-GINET21). Table S4. Empowerment in
newly diagnosed patients (CEO). Table S5. Questionnaire on patients’
opinions and use of the website in newly diagnosed patients (based on
constructs of the Technology Acceptance Model). Table S6A. Quality of
life (EORTC QLQ-C30). Table S6B. Quality of life (EORTC QLQ-GINET21).
Table S7. Empowerment (CEO). (DOCX 50 kb)
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